Study guide

11.2 Antimicrobial Stewardship and Infection Prevention

Board Certified Critical Care Pharmacist Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pathophysiology and Recognition of Critical Illness

1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness

2 Chapter 2: Medical Devices and Circulatory Support

2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care

3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management

3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation

4 Chapter 4: Vasoactive and Inotropic Therapy in Shock

4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock

5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)

5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness

6 Chapter 6: Cardiovascular Emergencies

6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias

7 Chapter 7: Pulmonary and Infectious Diseases in the ICU

7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU

8 Chapter 8: Neurocritical Care

8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury

9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies

9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy

10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition

10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral

11 Chapter 11: Quality, Safety, and Clinical Guidelines

11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions

12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine

12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management

13 Chapter 13: Treatment Planning and Care Coordination

13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education

11.2 Antimicrobial Stewardship and Infection Prevention

Key Takeaways Explain This Topic AI

Antimicrobial stewardship programs (ASPs) in the ICU aim to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, such as toxicity, selection of pathogenic organisms, and the emergence of resistance.

Critically ill patients exhibit altered pharmacokinetics (e.g., increased volume of distribution, augmented renal clearance) that necessitate optimized dosing strategies, such as prolonged infusions of beta-lactams.

Rapid diagnostic testing (RDT) coupled with active stewardship intervention significantly decreases time to optimal antimicrobial therapy.

De-escalation is a core stewardship principle in the ICU, involving the transition from broad-spectrum empiric therapy to targeted therapy based on culture results and clinical response.

Last updated: July 2026

The Intensive Care Unit accounts for a disproportionate amount of broad-spectrum antimicrobial use within hospitals. Patients in the ICU are at a high risk for healthcare-associated infections (HAIs) such as ventilator-associated pneumonia (VAP), central line-associated bloodstream infections (CLABSI), and catheter-associated urinary tract infections (CAUTI). Consequently, Antimicrobial Stewardship Programs (ASPs) are essential in the ICU to optimize therapy, improve patient outcomes, and combat the rising threat of multidrug-resistant organisms (MDROs).

Core Stewardship Strategies in the ICU

Effective ASPs in the critical care setting employ a variety of strategies to ensure appropriate antimicrobial use.

1. Prospective Audit and Feedback (PAF)

PAF involves an infectious diseases physician or stewardship pharmacist reviewing antimicrobial orders and providing direct, real-time feedback to the primary ICU team. This is often performed after 48-72 hours of therapy when culture data becomes available, prompting discussions on de-escalation, duration of therapy, or intravenous to oral (IV to PO) conversion.

2. Preauthorization

This strategy requires approval from an ASP member before certain restricted, broad-spectrum, or high-cost antimicrobials (e.g., ceftazidime-avibactam, meropenem-vaborbactam) can be dispensed. While effective at controlling the use of specific agents, it can be resource-intensive and potentially delay care if not implemented efficiently.

3. De-escalation

De-escalation is a fundamental concept in ICU stewardship. Critically ill patients with suspected sepsis often require prompt, broad-spectrum empiric therapy. However, once culture results and susceptibilities are available, therapy must be narrowed to target the specific pathogen. If cultures are negative and the patient has clinically improved, discontinuing antimicrobials entirely should be considered.

Pharmacokinetic and Pharmacodynamic (PK/PD) Optimization

Critically ill patients undergo profound physiologic changes that significantly alter drug PK/PD parameters. The "one size fits all" dosing approach is inappropriate in the ICU.

PK Parameter ICU Alteration Clinical Implication

Volume of Distribution (Vd) Increased due to fluid resuscitation, capillary leak, and hypoalbuminemia. Requires higher initial loading doses for hydrophilic drugs (e.g., beta-lactams, aminoglycosides, vancomycin) to achieve therapeutic target concentrations rapidly.

Clearance (Cl) May be increased (Augmented Renal Clearance) or decreased (Acute Kidney Injury). Requires vigilant monitoring and dynamic dose adjustments. Augmented renal clearance (ARC) may necessitate higher daily maintenance doses or more frequent administration.

Beta-Lactam Dosing Strategies

Beta-lactams (penicillins, cephalosporins, carbapenems) exhibit time-dependent bactericidal activity. Their efficacy is best predicted by the percentage of the dosing interval that the free drug concentration remains above the minimum inhibitory concentration (MIC) of the pathogen (% f T > MIC).

To optimize this PD target in the ICU, especially against less susceptible pathogens like Pseudomonas aeruginosa , extended or continuous infusions are often utilized. By infusing the drug over 3-4 hours (extended) or 24 hours (continuous) rather than the traditional 30 minutes, the time above the MIC is significantly prolonged, improving clinical cure rates.

Rapid Diagnostic Testing (RDT)

Traditional microbiological cultures can take 48-72 hours to yield species identification and susceptibility data. Rapid diagnostic tests, such as multiplex polymerase chain reaction (PCR), matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, and microarray technologies, can identify pathogens and genetic resistance markers within hours.

However, RDT alone is insufficient . Studies have consistently shown that RDT must be coupled with active antimicrobial stewardship intervention (e.g., a pharmacist calling the team with the results and a recommendation) to realize benefits such as decreased time to optimal therapy and reduced length of stay.

Infection Prevention Bundles

Pharmacists play a key role in supporting infection prevention efforts. This includes ensuring compliance with bundles for preventing HAIs:

VAP Bundles: Elevation of the head of the bed, daily "sedation vacations" and assessment of readiness to extubate, peptic ulcer disease (PUD) prophylaxis, and deep vein thrombosis (DVT) prophylaxis.

CLABSI Bundles: Maximum sterile barrier precautions during insertion, chlorhexidine skin antisepsis, optimal catheter site selection, and daily review of line necessity with prompt removal of unnecessary lines.

Clinical Scenario

A 55-year-old female is admitted with septic shock secondary to pneumonia. She receives fluid resuscitation and is started on empiric piperacillin-tazobactam and vancomycin. At 48 hours, she is hemodynamically stable and off vasopressors. Respiratory cultures grow Streptococcus pneumoniae sensitive to ceftriaxone. Blood cultures are negative.

Discussion: The stewardship pharmacist rounds with the ICU team and recommends de-escalation . The piperacillin-tazobactam and vancomycin should be discontinued, and therapy should be narrowed to ceftriaxone. Additionally, based on her clinical improvement, the pharmacist suggests defining a total treatment duration of 5-7 days rather than a prolonged 14-day course.